Le Lézard
Classified in: Health
Subject: FDA

Nexus Pharmaceuticals Receives FDA Approval for Sodium Nitroprusside Injection


VERNON HILLS, Ill., June 1, 2017 /PRNewswire/ -- Nexus Pharmaceuticals announced today the immediate availability in the United States of Sodium Nitroprusside Injection. Nexus Pharmaceuticals' Sodium Nitroprusside Injection is available as a single dose vial containing 50 mg per 2mL (25mg/mL) and is an AP Rated generic equivalent of Nitropress®.

Sodium Nitroprusside Injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure.

About Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals (www.nexuspharma.net) is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products. Through our high quality generic products, Nexus Pharmaceuticals is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. The company's headquarters is in Vernon Hills, Illinois.

Nitropress® is a registered trademark of Hospira Inc.

Media Contact
Nexus Pharmaceuticals Inc.
Ayesha Ahmed
847-996-3790
[email protected]

 

SOURCE Nexus Pharmaceuticals Inc.


These press releases may also interest you

at 11:45
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following...

at 11:45
Prostate Cancer Summit: Unveiling the Latest Strategies to Beat Prostate Cancer
Free Virtual Summit Brings Together Experts to Revolutionize Prostate Cancer Care and Treatment Key Takeaways: The Prostate Cancer Summit is a premier virtual event that aims to empower men with practical knowledge and strategies in their fight...

at 11:15
Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase
Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures....

at 11:03
Vajra Coffee Offers Chemical Free Naturally Decaffeinated Coffee
The heart of Vajra Coffee's natural decaffeination process lies in its adoption of the Swiss Water® Process, a natural method that removes 99% of caffeine...

at 11:00
United Imaging Healthcare Releases 2023 ESG Report, Advancing Mission of Equal Healthcare for Alltm
United Imaging Healthcare (SSE:688271) has published its 2023 Environment, Social, and Governance (ESG) Report, reaffirming its mission to bring Equal Healthcare for All. This report highlights the company's advancements in corporate responsibility,...

at 11:00
United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52%
United Imaging Healthcare (SSE:688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has released their 2023 annual report. The report reveals that the company achieved 11.41 billion CNY in revenue in 2023,...

More news about Health...


News published on and distributed by: